<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Once-daily dosing with insulin detemir and insulin glargine were compared in a double-blind, randomised, crossover study in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> subjects previously treated with other antihyperglycaemic medications </plain></SENT>
<SENT sid="1" pm="."><plain>Blood <z:chebi fb="105" ids="17234">glucose</z:chebi> was measured through continuous <z:chebi fb="105" ids="17234">glucose</z:chebi> monitoring (CGM) </plain></SENT>
<SENT sid="2" pm="."><plain>Insulin dose was adjusted daily during the titration phase to achieve target blood <z:chebi fb="105" ids="17234">glucose</z:chebi> values of (70-120 mg/dL) during the basal period, defined as 2400-0600 hours </plain></SENT>
<SENT sid="3" pm="."><plain>The last meal of the day started at 1800 h and basal insulin was injected at 2000 h </plain></SENT>
<SENT sid="4" pm="."><plain>The CGM data for a 24-h period on the second consecutive day after achieving target blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels were compared between treatments </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-nine subjects completed the study </plain></SENT>
<SENT sid="6" pm="."><plain>Over a 24-h measurement period, once-daily dosing with insulin detemir provided glycaemic control very similar to that of once-daily insulin glargine in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> after both had been titrated to the same <z:chebi fb="105" ids="17234">glucose</z:chebi> target </plain></SENT>
<SENT sid="7" pm="."><plain>Insulin detemir- and insulin glargine-treated subjects had similar mean 24-h <z:chebi fb="105" ids="17234">glucose</z:chebi> values (133 +/- 21 mg/dL compared with 126+/-20 mg/dL respectively, p = 0.385) and similar <z:chebi fb="105" ids="17234">glucose</z:chebi> values during the basal period (105 +/- 23 mg/dL compared with 98 +/- 19 mg/dL, respectively p = 0.204).Target basal glycaemic control was achieved in <z:hpo ids='HP_0000001'>all</z:hpo> subjects in a mean of 3.8 days for detemir and 3.5 days for glargine (p = 0.360) </plain></SENT>
<SENT sid="8" pm="."><plain>The mean dose of detemir was similar to that of glargine (26.3 and 26.6 units/day, respectively, p = 0.837) </plain></SENT>
<SENT sid="9" pm="."><plain>In this study, once-daily dosing of insulin detemir provided 24-h glycaemic control similar to that of insulin glargine in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>